Cell MedX Corp. (CMXC)
USD 0.43
(N/A%)
USD 0.43
(N/A%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | -313.43 Thousand USD | 29.63% |
| 2023 | -445.37 Thousand USD | 33.69% |
| 2022 | -671.69 Thousand USD | -38.11% |
| 2021 | -486.35 Thousand USD | 53.16% |
| 2020 | -1.03 Million USD | -16.77% |
| 2019 | -889.26 Thousand USD | 42.09% |
| 2018 | -1.53 Million USD | -28.24% |
| 2017 | -1.19 Million USD | 43.01% |
| 2016 | -2.1 Million USD | -103.58% |
| 2015 | -1.03 Million USD | -5471.14% |
| 2014 | -18.52 Thousand USD | -46.62% |
| 2013 | -12.63 Thousand USD | 20.32% |
| 2012 | -15.85 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | -268.35 Thousand USD | 39.75% |
| 2024 Q1 | -76.95 Thousand USD | -18.8% |
| 2024 Q2 | -42.56 Thousand USD | 44.69% |
| 2024 Q3 | 119.97 Thousand USD | 381.87% |
| 2024 Q4 | -116.96 Thousand USD | -197.49% |
| 2023 Q1 | -145 Thousand USD | 5.91% |
| 2023 FY | -445.37 Thousand USD | 33.69% |
| 2023 Q2 | -130.62 Thousand USD | 9.92% |
| 2023 Q3 | -105.83 Thousand USD | 18.98% |
| 2023 Q4 | -64.77 Thousand USD | 38.8% |
| 2022 Q1 | -239.35 Thousand USD | 29.87% |
| 2022 FY | -671.69 Thousand USD | -38.11% |
| 2022 Q4 | -154.1 Thousand USD | -36.81% |
| 2022 Q2 | -170.53 Thousand USD | 28.75% |
| 2022 Q3 | -112.64 Thousand USD | 33.95% |
| 2021 Q4 | -341.29 Thousand USD | -100.79% |
| 2021 Q1 | -194.75 Thousand USD | -9.87% |
| 2021 Q2 | -181.45 Thousand USD | 6.83% |
| 2021 FY | -486.35 Thousand USD | 53.16% |
| 2021 Q3 | -169.97 Thousand USD | 6.33% |
| 2020 Q2 | -299.7 Thousand USD | -25.75% |
| 2020 Q4 | -177.25 Thousand USD | 50.26% |
| 2020 Q1 | -238.33 Thousand USD | -73.53% |
| 2020 FY | -1.03 Million USD | -16.77% |
| 2020 Q3 | -356.33 Thousand USD | -18.89% |
| 2019 FY | -889.26 Thousand USD | 42.09% |
| 2019 Q4 | -137.34 Thousand USD | 64.39% |
| 2019 Q3 | -385.72 Thousand USD | -208.9% |
| 2019 Q2 | -124.86 Thousand USD | 48.26% |
| 2019 Q1 | -241.32 Thousand USD | -2.82% |
| 2018 Q1 | -825.36 Thousand USD | -306.02% |
| 2018 Q2 | -181.06 Thousand USD | 78.06% |
| 2018 FY | -1.53 Million USD | -28.24% |
| 2018 Q3 | -294.43 Thousand USD | -62.61% |
| 2018 Q4 | -234.71 Thousand USD | 20.28% |
| 2017 Q4 | 400.62 Thousand USD | 236.34% |
| 2017 Q1 | -257.16 Thousand USD | 23.02% |
| 2017 FY | -1.19 Million USD | 43.01% |
| 2017 Q3 | -293.83 Thousand USD | 71.94% |
| 2017 Q2 | -1.04 Million USD | -307.14% |
| 2016 Q3 | -296.01 Thousand USD | 38.28% |
| 2016 FY | -2.1 Million USD | -103.58% |
| 2016 Q4 | -334.08 Thousand USD | -12.86% |
| 2016 Q2 | -479.61 Thousand USD | 53.54% |
| 2016 Q1 | -1.03 Million USD | -253.1% |
| 2015 Q4 | -292.38 Thousand USD | 30.25% |
| 2015 FY | -1.03 Million USD | -5471.14% |
| 2015 Q3 | -419.19 Thousand USD | -53.74% |
| 2015 Q2 | -272.66 Thousand USD | -468.98% |
| 2015 Q1 | -47.92 Thousand USD | -788.93% |
| 2014 FY | -18.52 Thousand USD | -46.62% |
| 2014 Q1 | -5927.00 USD | -295.13% |
| 2014 Q4 | -5391.00 USD | -23.36% |
| 2014 Q2 | -2839.00 USD | 52.1% |
| 2014 Q3 | -4370.00 USD | -53.93% |
| 2013 Q4 | -1500.00 USD | 76.31% |
| 2013 Q2 | -4805.00 USD | 0.0% |
| 2013 FY | -12.63 Thousand USD | 20.32% |
| 2013 Q1 | - USD | 100.0% |
| 2013 Q3 | -6331.00 USD | -31.76% |
| 2012 Q2 | -5882.00 USD | 37.12% |
| 2012 Q3 | -4109.00 USD | 30.14% |
| 2012 Q4 | -2293.00 USD | 44.2% |
| 2012 Q1 | -9354.00 USD | 0.0% |
| 2012 FY | -15.85 Thousand USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| RetinalGenix Technologies Inc. | -2.08 Million USD | 84.982% |